{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"4"}],"units":"Participants"}],"description":"Determine the safety of Descartes-11 in patients with relapsed/refractory multiple myeloma","groups":[{"description":"Participants were administered Cyclophosphamide and Fludarabine for preconditioning\n\nParticipants were administered 10 million cells of Descartes-11 via intravenous catheter","id":"OG000","title":"Dose-Escalation Level 1"},{"description":"Participants were administered Cyclophosphamide and Fludarabine for preconditioning\n\nParticipants were administered 32 million cells of Descartes-11 via intravenous catheter","id":"OG001","title":"Dose Level 2"},{"description":"Participants were administered Cyclophosphamide and Fludarabine for preconditioning\n\nParticipants were administered 100 million cells of Descartes-11 via intravenous catheter","id":"OG002","title":"Dose Level 3"},{"description":"Participants were administered Cyclophosphamide and Fludarabine for preconditioning\n\nParticipants were administered 150 million cells of Descartes-11 via intravenous catheter","id":"OG003","title":"Dose Level 4A"},{"description":"Participants were administered Cyclophosphamide and Fludarabine for preconditioning\n\nParticipants were administered 150 million cells of Descartes-11 via intravenous catheter","id":"OG004","title":"Dose Level 4B"},{"description":"Participants were not administered Cyclophosphamide and Fludarabine for preconditioning\n\nParticipants were administered 100 million cells of Descartes-11 via intravenous catheter","id":"OG005","title":"Dose Level 4C"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants with treatment related adverse event","reportingStatus":"POSTED","timeFrame":"Time Frame: 21 days","title":"Number of Participants With Treatment-Related Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}